News
11d
Zacks Investment Research on MSNGSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...
3d
24/7 Wall St. on MSNPrediction: 1 Biotech Stock That Could Surpass Pfizer by 2030Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...
Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...
Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...
Brazil's Vice President Geraldo Alckmin stayed at home Monday after being diagnosed with Covid-19, Agencia Brasil reported. Alckin is also Minister of Development, Industry, Trade, and Services.
This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results